M. Alsina

J. Harousseau, M. Kharfan-Dabaja, R. Baz, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease

G. Roodman, Y. Gazitt, M. Alsina, 2001 .

Development of an in vivo model of human multiple myeloma bone disease.

F. Craig, G. Roodman, G. Mundy, 1996, Blood.

Multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic transplantation for high-risk multiple myeloma: Results of the BMT CTN 1302 Trial.

P. Hari, M. Pasquini, Q. Bashir, 2022, Transplantation and cellular therapy.

Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience.

Ling Zhang, K. Shain, D. Lebovic, 2011, Clinical lymphoma, myeloma & leukemia.

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2013, Leukemia.

Primary plasmacytoma involving mediastinal lymph nodes: A diagnostic mimicry of primary mediastinal lymphoma.

M. Kharfan-Dabaja, T. Nishihori, M. Alsina, 2016, Hematology/oncology and stem cell therapy.

Dynamic super-enhancer core regulatory circuits and epigenetic landscapes drive malignant progression and refractory disease in multiple myeloma

H. Dai, R. Gillies, R. Gatenby, 2021 .

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

C. Hofmeister, A. Krishnan, S. Singhal, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Dose escalating trial of 17-AAG with bortezomib (BZ) in patients with relapsed refractory multiple myeloma (MM)

P. Richardson, C. Mitsiades, A. Chanan-Khan, 2005 .

Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.

D. Podzamczer, G. Sirera, J. González-lahoz, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease.

G. Roodman, Y. Gazitt, S. J. Choi, 2001, The Journal of clinical investigation.

Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma.

F. Craig, G. Roodman, R. Devlin, 2000, Blood.

disease Development of an in vivo model of human multiple myeloma bone

G. Mundy, R. Devlin, B. Boyce, 2011 .

Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy

S. Jagannath, D. Siegel, F. Petrocca, 2018, Blood.

Systemic Light Chain Amyloidosis - Panel Members

A. Krishnan, S. Singhal, C. Huff, 2014 .

Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma.

R. Fonseca, S. Jagannath, A. Gualberto, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM).

A. Krishnan, S. Lonial, P. Richardson, 2006 .

HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma

W. Dalton, V. Gandhi, R. Nimmanapalli, 2008, British journal of haematology.

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.

S. Jagannath, S. Lonial, N. Munshi, 2022, The New England journal of medicine.

Sirolimus for treatment of steroid-refractory acute graft-versus-host disease

J. Perkins, J. Pidala, Jongphil Kim, 2010, Bone Marrow Transplantation.

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2014, Blood.

Bortezomib salvage followed by a Phase I/II study of bortezomib plus high‐dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma

W. Dalton, D. Sullivan, J. Pidala, 2012, British journal of haematology.

Extended follow‐up of a phase II trial in relapsed, refractory multiple myeloma:

B. Barlogie, S. Jagannath, S. Singhal, 2006, Cancer.

IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation

J. Pidala, A. Mishra, Jongphil Kim, 2017, Haematologica.

Bisphosphonates in multiple myeloma.

H. Goldschmidt, B. Djulbegovic, A. Glasmacher, 2001, The Cochrane database of systematic reviews.

Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization.

N. Callander, Y. Gazitt, J. Anderson, 1999, Journal of hematotherapy.

A phase 2 study of single-agent carﬁlzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .

Challenging Cases in Multiple Myeloma

R. Fonseca, M. Alsina, 2022 .

Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, Blood.

Clinical Pharmacokinetics, Metabolism, and Drug-Drug Interaction of Carfilzomib

K. Papadopoulos, J. Infante, C. Kirk, 2013, Drug Metabolism and Disposition.

Microsoft Word-68804888-file00

M. Alsina, 2012 .

Tables : 2 Figures : 4 Supplemental Tables : 6 Supplemental Figures : 2

M. Alsina, 2012 .

Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Long-Term Treatment and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

S. Jagannath, D. Siegel, R. Vij, 2010 .

Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects.

S. Jagannath, A. Jakubowiak, S. Lonial, 2009 .

Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma

J. Laubach, P. Richardson, J. Moslehi, 2018, British journal of haematology.

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

C. Hofmeister, S. Singhal, Rashmi Kumar, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.

N. Munshi, J. Laubach, P. Richardson, 2013, Blood.

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, Blood.

Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study

N. Raje, T. Kovacsovics, O. Landgren, 2019, American journal of hematology.

A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease

J. Pidala, A. Mishra, Jongphil Kim, 2021, Blood advances.

Updated Results of Bortezomib-Naïve Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM).

A. Jakubowiak, R. Vij, A. Belch, 2009 .

Melphalan Culprit or Confounder in Acute Encephalopathy during Autologous Hematopoietic Stem Cell Transplantation?

M. Alsina, J. Ochoa-Bayona, E. Ayala, 2012, Case reports in transplantation.

Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma

Christelle M Colin-Leitzinger, B. Sahaf, A. Mishra, 2022, Blood advances.

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.

D. Esseltine, B. Barlogie, P. Wen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.

H. McLeod, J. Lancet, S. Yoder, 2017, The Lancet. Oncology.

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

S. Lonial, P. Richardson, S. Coutre, 2013, Blood.

Multiple myeloma

S. Singhal, C. Huff, G. Tricot, 2001, Bone Marrow Transplantation.

Radiation therapy in AIDS-related cutaneous Kaposi's sarcoma.

C. Conill, I. Henríquez, M. Alsina, 1997, Dermatology.

Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.

C. Beam, W. Dalton, S. Sebti, 2005, Blood.

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.

G. Ahmann, R. Fonseca, B. Djulbegovic, 2004 .

Bone Marrow Stroma Confers Resistance to Apo2 Ligand/TRAIL in Multiple Myeloma in Part by Regulating c-FLIP1

W. Dalton, C. Anasetti, K. Shain, 2008, The Journal of Immunology.

Part by Regulating c-FLIP Apo2 Ligand/TRAIL in Multiple Myeloma in Bone Marrow Stroma Confers Resistance to

W. Dalton, C. Anasetti, K. Shain, 2008 .

of April 15 , 2017 . This information is current as Part by Regulating c-FLIP Apo 2 Ligand / TRAIL in Multiple Myeloma in Bone Marrow Stroma Confers Resistance

W. Dalton, C. Anasetti, K. Shain, 2008 .

Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.

C. Beam, W. Dalton, D. Boulware, 2003, Cancer research.

Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines.

Yulia Nefedova, W. Dalton, D. Gabrilovich, 2004, Blood.

Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis

G. Pinkus, M. Skinner, Shou-Jiang Gao, 2000, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma

M. Dimopoulos, S. Lonial, J. Laubach, 2015, Expert review of anticancer therapy.

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.

S. Jagannath, Hui-Yi Lin, D. Sullivan, 2016, Blood.

Phase II Study of Pomalidomide , Cyclophosphamide , and Dexamethasone in Relapsed Refractory Myeloma

S. Jagannath, Hui-Yi Lin, D. Sullivan, 2016 .

Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma

H. Jim, J. Pidala, C. Anasetti, 2013, Bone Marrow Transplantation.

Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow

W. Dalton, R. Widen, C. Anasetti, 2012, Clinical Cancer Research.

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

C. Hofmeister, A. Krishnan, S. Singhal, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

H. Goldschmidt, U. Mellqvist, M. Dimopoulos, 2016, Leukemia.

The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients with Cytopenia.

L. Moscinski, Ling Zhang, K. Shain, 2021, Clinical Lymphoma Myeloma and Leukemia.

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.

G. Mulligan, D. Esseltine, P. Sonneveld, 2012, Blood.

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.

Diane Warren, Edie Weller, S. Jagannath, 2006, Blood.

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

D. Esseltine, B. Barlogie, S. Jagannath, 2004, British journal of haematology.

Experimental Therapeutics , Molecular Targets , and Chemical Biology Targeting the Fanconi Anemia / BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma

W. Dalton, D. Boulware, L. Hazlehurst, 2009 .

Updated survival analyses after prolonged follow‐up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma

D. Esseltine, B. Barlogie, S. Jagannath, 2007, British journal of haematology.

ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation.

J. Perkins, J. Pidala, C. Anasetti, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study.

J. Pidala, C. Anasetti, F. Locke, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Bart Barlogie, Gordan Srkalovic, David Irwin, 2003, The New England journal of medicine.

Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation.

P. Hari, M. Pasquini, M. Qazilbash, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study.

J. Crowley, E. Kraut, S. Salmon, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concomitant de novo myeloid and plasma cell disorders are frequently associated with low-risk cytogenetic abnormalities : a single institutional clinicopathologic study of 32 cases

Ling Zhang, A. List, R. Komrokji, 2016 .

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma

D. Esseltine, B. Barlogie, S. Jagannath, 2005, Cancer.

Cytokine regulation of bone cell differentiation.

G. Roodman, T. A. Guise, M. Alsina, 1996, Vitamins and hormones.

Updates to the NCCN Guidelines

A. Krishnan, S. Singhal, C. Huff, 2013 .

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study

A. Krishnan, S. Lonial, P. Richardson, 2011, British journal of haematology.

Farnesyltransferase inhibitor FTI‐R115777 is well tolerat ed, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

G. Ahmann, R. Fonseca, B. Djulbegovic, 2003, Blood.

Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting.

J. Perkins, J. Pidala, J. Pinilla-Ibarz, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids

J. Perkins, J. Pidala, C. Anasetti, 2011, Haematologica.

Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience

J. Perkins, J. Pidala, A. Mishra, 2015, Bone Marrow Transplantation.

A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation

H. Jim, J. Perkins, J. Pidala, 2012, Haematologica.

A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis.

J. Perkins, W. Janssen, D. Sullivan, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Increased infections and delayed CD4+ T-cell but faster B-cell Immune Reconstitution after Posttransplant Cyclophosphamide Compared to Conventional GVHD prophylaxis in Allogeneic Transplantation.

J. Pidala, Junmin Whiting, A. Mishra, 2021, Transplantation and cellular therapy.

Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia.

J. Perkins, W. Janssen, J. Pidala, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.

A. Krishnan, S. Singhal, Rashmi Kumar, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results.

J. Pidala, A. Mishra, Jongphil Kim, 2015, Biology of Blood and Marrow Transplantation.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

C. Hofmeister, S. Singhal, Rashmi Kumar, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.

C. Hofmeister, S. Singhal, Rashmi Kumar, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

Anthony Boral, Hartmut Goldschmidt, Mario Boccadoro, 2007, Blood.

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.

Faith Davies, Edie Weller, Kenneth Anderson, 2004, Mayo Clinic proceedings.

Oral Weekly Cyclophosphamide in Combination with Pomalidomide and Dexamethasone for Relapsed and Refractory Myeloma: Report of the Dose Escalation Cohort

S. Jagannath, W. Dalton, D. Sullivan, 2012 .

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.

D. Esseltine, S. Jagannath, N. Munshi, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multiple myeloma, version 1.2013.

A. Krishnan, S. Singhal, Rashmi Kumar, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease

H. Jim, J. Pidala, A. Mishra, 2015, Haematologica.

An in vivo model of human multiple myeloma bone disease.

G. Roodman, G. Mundy, B. Boyce, 1995, Stem cells.

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, Blood.

Immunotherapy strategies for multiple myeloma: the present and the future.

F. Locke, M. Kharfan-Dabaja, T. Nishihori, 2013, Immunotherapy.

Immunotherapy strategies for multiple myeloma : the present & the future Review demonstrable after in vitro stimulation with autologous paraprotein

F. Locke, T. Nishihori, M. Alsina, 2010 .

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

S. Jagannath, D. Siegel, N. Munshi, 2019, Blood.

Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma

S. Jagannath, A. Jakubowiak, D. Siegel, 2021, Blood.

Multiple myeloma. Clinical practice guidelines in oncology.

J. Vose, S. Singhal, C. Huff, 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

CARDIAC EVENTS AFTER ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR T-CELL (IDECABTAGENE VICLEUCEL) FOR MULTIPLE MYELOMA

Dae Hyun Lee, F. Locke, B. Shah, 2022, Journal of the American College of Cardiology.

Management of multiple myeloma: a systematic review and critical appraisal of published studies.

B. Djulbegovic, B. Durie, T. Loughran, 2003, The Lancet. Oncology.

A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation.

J. Pidala, A. Mishra, Xuefeng Wang, 2021, Blood advances.

Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma

J. Perkins, T. Nishihori, M. Alsina, 2014, Bone Marrow Transplantation.

5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation

J. Perkins, W. Janssen, D. Sullivan, 2010, Bone Marrow Transplantation.

Administration of Rituximab Is Feasible and Does Not Affect Engraftment of Allograft Recipients with Advanced CD20+ Malignancies.

J. Perkins, D. Sullivan, L. Brand, 2007 .

High-dose melphalan produces favorable response in a patient with multiple myeloma and coexisting essential thrombocythemia with JAK2 mutation

K. Shain, M. Kharfan-Dabaja, T. Nishihori, 2014, Bone Marrow Transplantation.

Lenalidomide‐based response‐adapted therapy for older adults without high risk myeloma

B. Fridley, D. Sullivan, J. Brayer, 2018, British journal of haematology.

An Evolutionary Approach for Personalized Therapy in Multiple Myeloma

A. Silva, K. Shain, R. Baz, 2016 .

An open‐label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma

W. Dalton, Jongphil Kim, B. Yue, 2015, European journal of haematology.

Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma

Michael L. Wang, D. Siegel, R. Orlowski, 2013, Clinical Cancer Research.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carﬁlzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .

Novel Therapeutic Options for the Treatment of Relapsed and Relapsed, Refractory Myeloma

P. Richardson, M. Alsina, 2007 .

Busulfan Area-under-the-Curve Finding Study within a Busulfan/Fludarabine (BuFlu) Conditioning Regimen before Allogeneic Hematopoietic Cell Transplantation (HCT).

J. Perkins, W. Janssen, C. Anasetti, 2006 .

Case Report of IgM Multiple Myeloma

M. Alsina, Javier Cerra, William Cáceres-Pérkins, 2018, Cancer control : journal of the Moffitt Cancer Center.

Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM): Final Results of a Multicenter Phase 1 Trial.

S. Jagannath, N. Munshi, P. Richardson, 2006 .

Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization

M. Schell, J. Perkins, J. Pidala, 2013, Bone Marrow Transplantation.

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

P. Richardson, Shaji K. Kumar, D. Reece, 2009, British journal of haematology.

A Randomized, Controlled Trial of Graft-Versus-Host Disease (GVHD) Prophylaxis Comparing Tacrolimus and Mycophenolate Mofetil to Tacrolimus and Methotrexate: Analysis of GVHD, Relapse and Survival

M. Schell, J. Perkins, Jongphil Kim, 2009 .

Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd

H. Jim, J. Perkins, J. Pidala, 2011 .

Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up

D. Esseltine, S. Jagannath, A. Jakubowiak, 2010 .

Time To Event Analyses in PANORAMA 2: A Phase 2 Study Of Panobinostat, Bortezomib, and Dexamethasone In Patients With Relapsed and Bortezomib-Refractory Multiple Myeloma

S. Lonial, P. Richardson, S. Coutre, 2013 .

Targeted Intravenous Busulfan Combined with Fludarabine (tBuFlu) as Conditioning Prior to Allogeneic Peripheral Blood Stem Cell Transplant: Early Results of Low Treatment Related Mortality.

J. Perkins, W. Janssen, C. Anasetti, 2005 .

A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma

S. Trudel, O. O’Connor, A. Goy, 2012, Clinical Cancer Research.

Ethical challenges with multiple myeloma BCMA CAR-T slot allocation: a multi-institution experience.

N. Raje, S. Holstein, S. Mailankody, 2023, Transplantation and cellular therapy.

A Phase 1 Trial of Lenalidomide (REVLIMID®) with Bortezomib (VELCADE®) in Relapsed and Refractory Multiple Myeloma.

S. Jagannath, N. Munshi, P. Richardson, 2005 .

Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes

S. Jagannath, A. Jakubowiak, D. Siegel, 2020 .

Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium

P. Voorhees, D. Sborov, F. Locke, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Retrospective Comparison Of Secondary Mobilization Strategies In Candidates For Autologous Hematopoietic Cell Transplantion With A Focus On Resource Utilization: Plerixafor+G-CSF Versus Other Regimens

J. Perkins, K. Daily, C. Anasetti, 2010 .

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2008 .

Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma.

F. Craig, G. Roodman, M. Dallas, 2001, Experimental hematology.

Assessment of Clonotypic Rearrangements and Minimal Residual Disease in Lymphoid Malignancies: A Large Cancer Center Experience Using clonoSEQ.

J. Pinilla-Ibarz, L. W. Lee, B. Shah, 2021, Archives of pathology & laboratory medicine.

Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study.

K. Anderson, A. Krishnan, S. Lonial, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and Activity of KOS-953 in Patients with Relapsed Refractory Multiple Myeloma (MM): Interim Results of a Phase 1 Trial.

P. Richardson, C. Mitsiades, A. Chanan-Khan, 2005 .

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

A. Jakubowiak, Shaji K. Kumar, B. Laplant, 2022, Blood.

Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM): Initial Analysis of Safety Data

A. Jakubowiak, Shaji K. Kumar, B. Laplant, 2020 .

Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience.

P. Voorhees, D. Sborov, F. Locke, 2022, Journal of Clinical Oncology.

A Phase II Study of PXD101 in Advanced Multiple Myeloma.

S. Singhal, A. Waage, M. Schuster, 2006 .

Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study

S. Jagannath, Hui-Yi Lin, D. Sullivan, 2014 .

Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose‐escalation study

P. Richardson, C. Mitsiades, A. Chanan-Khan, 2010, British journal of haematology.

Pre-Transplant 5-Azacitidine (Vidaza®) May Improve Outcome of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Myelodysplastic Syndrome (MDS).

J. Perkins, W. Janssen, C. Anasetti, 2006 .

Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.

C. Beam, W. Dalton, S. Sebti, 2005, Blood.

Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.

D. Siegel, N. Raje, T. Kovacsovics, 2018 .

PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort.

S. Jagannath, A. Jakubowiak, R. Vij, 2009 .

Deacetylase inhibitors: an advance in myeloma therapy?

H. Einsele, S. Lonial, J. Laubach, 2017, Expert review of hematology.

Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM).

R. Orlowski, N. Gabrail, W. Bensinger, 2009 .

European Obesity Summit (EOS) – Joint Congress of EASO and IFSO-EC, Gothenburg, Sweden, June 1 – 4, 2016: Abstracts

Parashu Ram Pal, S. A. Todd, Jimmy D Bell, 2016, Obesity Facts.

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2011 .

Phase II Study of the Pan-Deacetylase Inhibitor Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and Bortezomib-Refractory Multiple Myeloma (PANORAMA 2)

S. Lonial, P. Richardson, G. Warsi, 2011 .

Sequence of novel agents in multiple myeloma: an instrumental variable analysis.

B. Djulbegovic, W. Dalton, D. Sullivan, 2013, Leukemia research.

Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma

O. Hampton, Q. Mo, Mingxiang Teng, 2022, Blood advances.

Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study.

J. Brayer, K. Shain, F. Reu, 2022, Clinical lymphoma, myeloma & leukemia.

Long-term responses observed with lenalidomide therapy for patients with relapsed or refractory multiple myeloma

S. Jagannath, P. Richardson, J. Zeldis, 2008 .

A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.

Michael L. Wang, A. Jakubowiak, S. Lonial, 2007, Clinical advances in hematology & oncology : H&O.

Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma.

F. Craig, S. Meri, G. Roodman, 2000, Blood.

Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study

S. Jagannath, A. Jakubowiak, S. Lonial, 2011 .

PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis.

S. Jagannath, A. Jakubowiak, S. Lonial, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM).

D. Siegel, S. Singhal, P. Hari, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM)

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience

P. Voorhees, M. Hildebrandt, D. Sborov, 2022, Blood.

Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM)

A. Jakubowiak, T. Zimmerman, P. Richardson, 2008 .

Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .

Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma

Abhishek Kumar, J. Brayer, F. Locke, 2023, Blood advances.

KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation

R. Vij, X. Leleu, R. Ananthakrishnan, 2022, Blood.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

C. Hofmeister, S. Singhal, Rashmi Kumar, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.

A. Krishnan, S. Singhal, Rashmi Kumar, 2012, The Journal of the National Comprehensive Cancer Network.

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

D. Sullivan, J. Brayer, Jongphil Kim, 2019, Blood.

PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma

S. Lonial, P. Richardson, S. Coutre, 2012 .

Phase 1 Dose Escalation Study of the Monoclonal Antibody Against the Insulin Like Growth Factor I Receptor CP-751,871 in Patients with Multiple Myeloma.

R. Fonseca, S. Jagannath, P. Richardson, 2007 .

A Multiple Myeloma Research Consortium (MMRC) Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM): Updated Results.

A. Jakubowiak, T. Zimmerman, P. Richardson, 2007 .

Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM).

B. Barlogie, S. Jagannath, S. Lonial, 2006 .

Phase 1 clinical trial of KOS-953 + bortezomib (BZ) in relapsed refractory multiple myeloma (MM).

S. Lonial, P. Richardson, C. Mitsiades, 2005, Journal of Clinical Oncology.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

C. Hofmeister, A. Krishnan, S. Singhal, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel

H. Jim, A. Hoogland, B. Gonzalez, 2023, Cancers.

HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma

W. Dalton, V. Gandhi, R. Nimmanapalli, 2008, British journal of haematology.

Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results.

J. Pidala, A. Mishra, Jongphil Kim, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease

J. Pidala, A. Mishra, Jongphil Kim, 2022 .

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2014, Blood.

KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation

R. Vij, P. Hari, N. Raje, 2022, Blood.

Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting.

J. Perkins, J. Pidala, J. Pinilla-Ibarz, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Updated Results of Phase II Study of Cyclophosphamide(Cy), Bortezomib(Bz), Pegylated Doxorubicin(DOX), and Dexamethasone(dex), (CVDD), in Patients with Newly Diagnosed Myeloma:an Effective Induction Regimen for High Risk Disease

W. Dalton, D. Sullivan, Jongphil Kim, 2012 .

Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM)

A. Jakubowiak, T. Zimmerman, P. Richardson, 2010 .

Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience.

Ling Zhang, K. Shain, D. Lebovic, 2011, Clinical lymphoma, myeloma & leukemia.

PANORAMA 2: A phase II study of panobinostat (LBH589) in combination with bortezomib (BTZ) and dexamethasone (DEX) in patients with relapsed and BTZ-refractory multiple myeloma (MM).

S. Lonial, P. Richardson, G. Warsi, 2010 .

NCCN clinical practice guidelines in oncology: multiple myeloma.

J. Vose, C. Huff, A. Chanan-Khan, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .